Orforglipron vs Tirzepatide
Orforglipron is an oral small-molecule GLP-1 agonist; tirzepatide is an injected peptide dual agonist. Both come from the same developer.
Orforglipron
An oral, small-molecule (non-peptide) GLP-1 receptor agonist taken once daily without food restrictions.
BEST STUDIED FOR
Incretin & metabolic
Read the cited profile →
Tirzepatide
Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 incretin receptors.
BEST STUDIED FOR
Dual-agonist (GIP/GLP-1) metabolic research
FREE GIFTFree GHK-Cu 50 mg with every Tirzepatide 30mg vial and free GHK-Cu 100 mg with every Tirzepatide 60mg vial, until 15 Oct — one per vial, added automatically at checkout.
Side by side · to buy
Price, purity and dispatch
| Compare | Orforglipron | Tirzepatide30 mg · more sizes |
|---|---|---|
| Price | — | fromR1,399 |
| Cost per mg | — | R46.6 / mg |
| Purity (Janoshik) | — | 99.927%HPLC, published |
| Stock | — | Restocking |
| Dispatch | — | When restocked |
| Certificate | — | View CoA → |
| Literature | — | 3 papers → |
| Research focus | Incretin & metabolic | Dual-agonist (GIP/GLP-1) metabolic research |
| Read the cited profile | Notify me |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
SIDE BY SIDE
| Orforglipron | Tirzepatide | |
|---|---|---|
| The key difference | Oral, GLP-1 only | Injected, GIP + GLP-1 |
| Class | Incretin & metabolic | Incretin & metabolic |
| Mechanism | Orforglipron activates the GLP-1 receptor despite not being a peptide: structural studies show it binds a pocket distinct from GLP-1 itself, producing biased signalling. | Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 incretin receptors. |
| Status | Phase 3 programme in type 2 diabetes and obesity (2025–2026), including a head-to-head versus oral semaglutide. | An approved medicine (US/EU) for type 2 diabetes and obesity. |
| Reported safety signals | Phase 1–3 trials report the class gastrointestinal profile. | Phase 3 trials reported mainly gastrointestinal adverse events (nausea, diarrhoea, vomiting). |
| A key study | A phase 2 trial measured weight change with once-daily oral orforglipron in adults with obesity. (N Engl J Med 2023, PMID 37351564) | The discovery-to-proof-of-concept study characterising LY3298176 (tirzepatide) as a novel dual GIP/GLP-1 receptor agonist. (Mol Metab 2018, PMID 30473097) |
WHEN TO RESEARCH WHICH
The comparison is route and receptor breadth: oral convenience on one side, dual-agonist potency on the other. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Orforglipron] Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity — N Engl J Med 2023. PMID 37351564
- [Orforglipron] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment — N Engl J Med 2025. PMID 40960239
- [Orforglipron] Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist — Proc Natl Acad Sci U S A 2020. PMID 33177239
- [Tirzepatide] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept — Mol Metab 2018. PMID 30473097
- [Tirzepatide] Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes — N Engl J Med 2021. PMID 34170647
- [Tirzepatide] Tirzepatide Once Weekly for the Treatment of Obesity — N Engl J Med 2022. PMID 35658024
FREQUENTLY ASKED
What is the difference between Orforglipron and Tirzepatide?
Orforglipron is an oral small-molecule GLP-1 agonist; tirzepatide is an injected peptide dual agonist. Both come from the same developer.
What is the regulatory status of Orforglipron and Tirzepatide?
Orforglipron: Phase 3 programme in type 2 diabetes and obesity (2025–2026), including a head-to-head versus oral semaglutide. Tirzepatide: An approved medicine (US/EU) for type 2 diabetes and obesity.
What safety signals have been reported?
Orforglipron: Phase 1–3 trials report the class gastrointestinal profile. Tirzepatide: Phase 3 trials reported mainly gastrointestinal adverse events (nausea, diarrhoea, vomiting).
Which studies is this comparison based on?
For Orforglipron: “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity” (PMID 37351564); “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment” (PMID 40960239); “Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist” (PMID 33177239). For Tirzepatide: “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept” (PMID 30473097); “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes” (PMID 34170647); “Tirzepatide Once Weekly for the Treatment of Obesity” (PMID 35658024).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use